
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+3
Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website
Drug development,stapled peptides,biopharmaceuticals,chemistry,chemoprotection,myelopreservation,chemotherapy,and supportive care
Aileron therapeutics operates in the Biotechnology research industry.
Aileron therapeutics's revenue is 11m - 100m
Aileron therapeutics has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.